Skip to main content



At WMS we are proud to have a dedicated Cancer Research Centre, bringing together colleagues from across the University of Warwick to collaborate on research projects. Several of our other teams at WMS are also involved in cancer research, with current work focusing on breast cancer, prostate cancer, colorectal cancer, throat cancer and myloma.

Cancer Research Centre


The Warwick Cancer Research Centre is a unique and inter-disciplinary research centre in the UK Midlands, where we fuse cancer clincial trials with clinical services.

Clinical Trials Unit


The Clinical Trials Unit works in the area of cancer and is currently running cancer trials, specifically breast cancer (OPTIMA and MAMMO-50), throat cancer (De_ESCALATE) and myloma (TEAMM).

Warwick Evidence


Warwick Evidence works in the area of cancer by undertaking reviews and evidence synthesis on the clinical and cost-effectiveness of health care interventions for the NIHR Health Technology Assessment Programme on behalf of a range of policy makers, including the National Institute for Health and Care Excellence (NICE). A number of reports specifically review cancer drugs.

CLAHRC (Collaboration for Leadership in Applied Health Research and Care)


The CLARHC (Collaboration for Leadership in Allied Health Research and Care) works in the area of cancer through its Theme 3 ‘Prevention and detection of diseases’ , conducting research into the update and outcomes from colorectal and breast screening programmes as well as health checks.

Warwick Primary Care

Primary care

Warwick Primary Care is working in the area of cancer through its partnership in prostate cancer; the feasibility of an integrated system to improve patient outcomes and experience (ICARE-P Study). The aim of this study is to test the feasibility of undertaking a full trial to compare a new model of prostate cancer care with standard care.

Health Economics


Members of the Centre for Health Economics are involved in projects that concern cancer drugs: Systematic reviews, trials and HTA technology appraisals.